Myeloma

Myeloma overview

Myeloma is a rare blood cancer that begins in plasma cells, a type of white blood cell normally responsible for producing antibodies that help fight off infectious pathogens and other threats.

Read more

Myeloma treatment

While myeloma treatment can drive the disease into remission, sometimes for long periods of time, the cancer will often come back after a few months or years, and additional treatments will be needed.

Read more

Latest news

trial of myeloma drug Aplidin for COVID-19

April 20, 2020 by Inês Martins, PhD

Spain Reviewing Trial to Treat COVID-19 Pneumonia With Myeloma Therapy Aplidin

Madrid-based PharmaMar has submitted the protocol for a…

melflufen accelerated approval request

April 13, 2020 by Joana Carvalho, PhD

Bristol Myers, Bluebird Bio Seek FDA Approval of Ide-cel to Treat Advanced Multiple Myeloma

Bristol Myers Squibb and Bluebird…

Phase 2 trial results

April 6, 2020 by Vanessa Pataia

Melflufen Shows Positive Response in Triple-refractory Multiple Myeloma Trial

Topline results show a 26% response rate in a…

Xpovio approval request

March 30, 2020 by Marta Figueiredo, PhD

Oncopeptides’ Accelerated Approval Filing for Melflufen in US Unimpeded by COVID-19

Despite some interruptions to melflufen‘s (melphalan flufenamide) clinical…

genetic test for high-risk myeloma

March 23, 2020 by Marisa Wexler, MS

Genetic Test May Help Identify Ultra High-risk Multiple Myeloma

A novel genetic test could help identify people with…

cevostamab

March 20, 2020 by Iqra Mumal, MSc

Ninlaro Combo Fails to Extend New Myeloma Patients’ Survival Without Disease Worsening

A combination of Ninlaro (ixazomib), Revlimid (lenalidomide),…

Prev
1
…
29
30
31
32
33
34
35
…
99
Next

Editorial team

Expert PhD science editors, writers, and journalists dedicated to credible reporting.

Ana de Barros, PhD

Patricia Silva, PhD

Ines Martins, PhD

Meet our team